Invesco
DYN icon

Invesco’s Dyne Therapeutics DYN Stock Holding History

Invesco’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.66M Sell
164,598
-84,343
-34% -$1.57M ﹤0.01% 2342
2026
Q1 		$4.51M Buy
248,941
+111,257
+81% +$1.92M ﹤0.01% 2241
2025
Q4 		$2.69M Buy
137,684
+20,121
+17% +$381K ﹤0.01% 2491
2025
Q3 		$1.49M Buy
117,563
+35,421
+43% +$404K ﹤0.01% 2744
2025
Q2 		$782K Buy
82,142
+15,849
+24% +$174K ﹤0.01% 2953
2025
Q1 		$693K Buy
66,293
+25,970
+64% +$371K ﹤0.01% 3020
2024
Q4 		$950K Sell
40,323
-2,099
-5% -$62.1K ﹤0.01% 2939
2024
Q3 		$1.52M Sell
42,422
-217,432
-84% -$8.65M ﹤0.01% 2735
2024
Q2 		$9.17M Buy
259,854
+9,814
+4% +$285K ﹤0.01% 1843
2024
Q1 		$7.1M Buy
250,040
+174,868
+233% +$3.95M ﹤0.01% 2018
2023
Q4 		$1,000K Sell
75,172
-19,223
-20% -$188K ﹤0.01% 2893
2023
Q3 		$846K Buy
94,395
+25,354
+37% +$273K ﹤0.01% 2943
2023
Q2 		$777K Sell
69,041
-171,853
-71% -$2.03M ﹤0.01% 3013
2023
Q1 		$2.78M Buy
240,894
+106,116
+79% +$1.38M ﹤0.01% 2505
2022
Q4 		$1.56M Sell
134,778
-2,959
-2% -$34.2K ﹤0.01% 2733
2022
Q3 		$1.75M Buy
137,737
+126,391
+1,114% +$1.45M ﹤0.01% 2695
2022
Q2 		$78K Sell
11,346
-352
-3% -$2.42K ﹤0.01% 3927
2022
Q1 		$112K Buy
11,698
+292
+3% +$2.49K ﹤0.01% 3860
2021
Q4 		$136K Sell
11,406
-135
-1% -$1.9K ﹤0.01% 3855
2021
Q3 		$187K Buy
11,541
+1,587
+16% +$28.1K ﹤0.01% 3825
2021
Q2 		$209K Buy
+9,954
New +$187K ﹤0.01% 3772

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco's DYN Position: Q2 2026 in Review

Invesco reduced its Dyne Therapeutics (DYN) stake by 34% in Q2 2026, selling an estimated $1.57M and leaving 164,598 shares worth $3.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2342.

Invesco first reported a position in DYN in Q2 2021 and has held it in 21 quarters since. The position peaked at $9.17M in Q2 2024. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Invesco held 164,598 shares of Dyne Therapeutics worth $3.66M as of Q2 2026.
  • Invesco sold 84,343 Dyne Therapeutics shares in Q2 2026, an estimated $1.57M.
  • Dyne Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2342 holding.
  • Invesco first reported a position in Dyne Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Invesco's Dyne Therapeutics position peaked at $9.17M in Q2 2024.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.